Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06319027 · ClinicalTrials.gov registry record · Phase 2

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

A Phase 2 study of Glioblastoma, IDH-wildtype, sponsored by ECOG-ACRIN Cancer Research Group.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
1
Study location

NCT06319027 is a Phase 2 study of Glioblastoma, IDH-wildtype that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 100 participants, below the 271-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06319027, a Phase 2 study of Glioblastoma, IDH-wildtype, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.

Conditions Studied

Glioblastoma, IDH-wildtype

Interventions

  • PROCEDURE Positron Emission Tomography
  • OTHER Fluciclovine F18
  • PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
  • DRUG Gadolinium-Chelate
  • PROCEDURE Magnetic Resonance Spectroscopy

Study Locations (1)

Wisconsin

  • University of Wisconsin Carbone Cancer Center - University Hospital - Madison

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-04-11
Est. Completion 2027-05-31
Phase Phase 2

Sponsor

ECOG-ACRIN Cancer Research Group

75 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06319027

The ClinicalTrials.gov registry entry for NCT06319027 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 271-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (63% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma, IDH-wildtype appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.

NCT06319027 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06319027 about?

NCT06319027 is a clinical study titled "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial". This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI)....

What is the current status of trial NCT06319027?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-04-11. Estimated completion is 2027-05-31.

What conditions does trial NCT06319027 study?

This clinical trial studies the following conditions: Glioblastoma, IDH-wildtype.

What interventions are being tested in trial NCT06319027?

The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Fluciclovine F18 (OTHER), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Gadolinium-Chelate (DRUG), Magnetic Resonance Spectroscopy (PROCEDURE).

Who is sponsoring clinical trial NCT06319027?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06319027 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma, IDH-wildtype

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma, IDH-wildtype

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.